Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data
Caitlyn T Solem,1 Ahmed Shelbaya,2,3 Yin Wan,1 Chinmay G Deshpande,1 Jose Alvir,2 Elizabeth Pappadopulos2 1Pharmerit International, Real World Evidence/Data Analytics, Bethesda, MD, 2Pfizer, Inc., Global Health Outcomes, New York, NY, 3Epidemiology Department of Mailman’s School of Public...
Guardado en:
Autores principales: | Solem CT, Shelbaya A, Wan Y, Deshpande CG, Alvir J, Pappadopulos E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8ba3c7088c2e4b2b90469b6784c6789a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low Y, et al.
Publicado: (2018) -
Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021) -
Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016) -
Non-Persistence with Medication as a Mediator for the Social Inequality in Risk of Major Adverse Cardiovascular Events in Patients with Incident Acute Coronary Syndrome: A Nationwide Cohort Study
por: Boesgaard Graversen C, et al.
Publicado: (2021) -
Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)